TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen
Source: SeekingAlpha
2026-05-27 08:08:22 ET
More on TG Therapeutics
- TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
- TG Therapeutics: Flawless Execution And $500 Million Non-Dilutive Capital Bolster Outlook
- TG Therapeutics: Briumvi Performance Aiding Upside, Buybacks Limiting Downside
- TG Therapeutics outlines $925M 2026 global revenue guidance while targeting ~$220M Q2 U.S. BRIUMVI net revenue
- TG Therapeutics GAAP EPS of $0.12 misses by $0.15, revenue of $204.92M beats by $3.71M
Read the full article on Seeking Alpha
For further details see:
TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen
TG Therapeutics Inc.
NASDAQ: TGTX
TGTX Trading
10.56% G/L:
$40.525 Last:
1,587,892 Volume:
$38.57 Open:
TGTX Latest News
June 03, 2026 07:30:00 am
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
June 02, 2026 07:30:00 am
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
June 01, 2026 07:30:00 am
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
May 28, 2026 07:30:00 am
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TGTX Stock Data
$4,661,971,279
141,867,445
0.11%
146
N/A
Biotechnology & Life Sciences
Healthcare
US
Morrisville
